hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06345014 id: 23CP40803 briefTitle: The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome overallStatus: RECRUITING date: 2023-12-20 date: 2025-12-30 date: 2026-03-30 date: 2024-04-03 date: 2024-04-04 name: AJU Pharm Co., Ltd. class: INDUSTRY name: OM Pharma SA briefSummary: This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome conditions: Chronic Prostatitis conditions: Chronic Pelvic Pain Syndrome studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Once a subject voluntarily gives written consent to participate in this study, a screening test will be conducted to evaluate their eligibility. Subjects determined to be eligible to participate in the study on Visit 2 (baseline) will be enrolled, randomized 1:1 either to the test group (OM-89 \[Uro-Vaxom® Capsule\]) or the control group (placebo of OM-89) and administered the investigational product for 26 weeks.
In parallel, an alpha blocker (alfuzosin 10 mg) will be administered for the first 13 weeks as a background treatment, followed by the placebo of alfuzosin until Week 26. The efficacy and safety will be checked until Week 52 from the start of the treatment for all subjects. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Background treatment - Xatral® XL Tab. 10 mg (alfuzosin hydrochloride): With the treatment of the investigational product, it will be administered for the first 13 weeks (Administration of the placebo will be continued to maintain the treatment compliance and blinding for the rest 13 weeks).
After week 13, Background treatment will be blinded for subject only until end of treatment period(Week 26). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 332 type: ESTIMATED name: OM-89 [Uro-Vaxom® Capsule] name: OM-89 Placebo [Uro-Vaxom® Capsule Placebo] measure: NIH-CPSI total score measure: NIH-CPSI domain score measure: Subject and Investigator's Global Assessment sex: MALE minimumAge: 19 Years maximumAge: 55 Years stdAges: ADULT facility: AJU Pharm Co., Ltd. status: RECRUITING city: Seoul country: Korea, Republic of name: JUNGMIN LEE role: CONTACT phone: +82-02-2630-0700 email: ajuf13001@ajupharm.co.kr lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06345001 id: 22261 briefTitle: A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-08-12 date: 2024-08-30 date: 2024-04-03 date: 2024-04-29 name: Bayer class: INDUSTRY briefSummary: Researchers are studying a new potential treatment for liver cancer.
As the study interventions are not yet treatments for liver cancer, access to BAY3630942 and BAY3547922 after the end of the study will not be required. conditions: Hepatocellular Carcinoma (HCC) studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 17 type: ESTIMATED name: BAY3630942 name: BAY3547922 measure: Radioactivity concentration (SUVmean, %ID/g) of BAY3630942 in normal organs (including but not limited to kidney, spleen, liver, and bone marrow) as a function of time using 3 post-administration PET/CT scans measure: Zirconium-89 absorbed doses (mGy/MBq) in normal organs measure: Absorbed doses (mGy/MBq) from actinium-225 and daughter radionuclides in critical organs estimated measure: Proportion and severity of adverse events (AEs) after administration of BAY3630942 and BAY3547922 measure: Cmax (from zirconium-89 radioactivity concentration (Bq/g and %ID/kg) as a function of time in blood) measure: AUC (from zirconium-89 radioactivity concentration (Bq/g and %ID/kg) as a function of time in blood) measure: Cmax (from plasma concentration of total antibody (mg/L and %ID/L) as a function of time) measure: AUC (from plasma concentration of total antibody (mg/L and %ID/L) as a function of time) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: HonorHealth city: Scottsdale state: Arizona zip: 85258 country: United States lat: 33.50921 lon: -111.89903 facility: University of Southern California Keck School of Medicine city: Los Angeles state: California zip: 90089 country: United States lat: 34.05223 lon: -118.24368 facility: Biogenix Molecular, LLC city: Miami state: Florida zip: 33165 country: United States lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06344988 id: 2023/41-10 briefTitle: Physical and Functional Effects of Online Exercise Program on Musicians Playing Stringed Instruments overallStatus: RECRUITING date: 2024-01-22 date: 2024-06 date: 2025-01 date: 2024-04-03 date: 2024-04-03 name: Bandırma Onyedi Eylül University class: OTHER briefSummary: Musculoskeletal problems related to instrument playing or performance are frequently seen in musicians. Different interventions such as strength training, endurance training and yoga have been used in the management of these problems. The first specific exercise program for professional orchestra musicians was developed by Chan et al. However, it has been stated that it is difficult to encourage musicians' participation in exercise due to their constantly changing work schedules, and at this point, the use of digital media such as DVDs, USBs, and educational exercise videos may have a potential role.
On the other hand, it has been stated that smart wearable devices with mobile applications (such as smart watches, smart band) as digital health interventions are an interesting, interactive and efficient psychological strategy to promote physical activity and can be used as an intervention to promote a healthy lifestyle. Based on the literature, in our study, the exercise program developed by Chan et al., will be done online via "Google Meet" and symptoms can be evaluated with objective evaluation methods. Unlike other studies using digital media, exercises will be performed synchronously and feedback will be given to the musicians simultaneously, as in face-to-face exercises. In addition, all participants will be given a smart band, they will be encouraged to use it until the end of the study, and the change in their physical activity levels will be evaluated. conditions: Musculoskeletal Diseases or Conditions conditions: Musculoskeletal Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 38 type: ESTIMATED name: The exercise program name: Online education presentation name: Smart band measure: Musculoskeletal problems measure: Muscle oxygenation measure: Pressure pain threshold measure: Reaction time measure: Grip strength measure: Upper extremity function measure: Physical activity level sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bursa Regional State Symphony Orchestra status: RECRUITING city: Bursa zip: 16000 country: Turkey name: Umut Çanakçı, Musician role: CONTACT phone: +90 (224) 225 59 70 name: Sule Kecelioglu, MSc role: PRINCIPAL_INVESTIGATOR name: Selnur Narin Aral, Assoc. Prof. role: SUB_INVESTIGATOR lat: 40.19559 lon: 29.06013 facility: Bursa Uludağ University Faculty of Education Fine Arts Education Department, Department of Music Education status: RECRUITING city: Bursa zip: 16285 country: Turkey name: Gülnihal Gül, Assoc. Prof. role: CONTACT phone: +90 (224) 294 09 42 name: Sule Kecelioglu, MSc role: PRINCIPAL_INVESTIGATOR name: Selnur Narin Aral, Assoc. Prof. role: SUB_INVESTIGATOR lat: 40.19559 lon: 29.06013 facility: Bursa Uludağ University State Conservatory status: RECRUITING city: Bursa zip: 16285 country: Turkey name: Görkem Çalgan, Prof. Dr. role: CONTACT phone: +90 (224) 294 27 00 name: Sule Kecelioglu, MSc role: PRINCIPAL_INVESTIGATOR name: Selnur Narin Aral, Assoc. Prof. role: SUB_INVESTIGATOR lat: 40.19559 lon: 29.06013 facility: Ege University State Conservatory of Turkish Music status: RECRUITING city: İzmir zip: 35100 country: Turkey name: Nurdan Gürtunca, Assoc. Prof. role: CONTACT phone: +90 (232) 311 29 44 name: Sule Kecelioglu, MSc role: PRINCIPAL_INVESTIGATOR name: Selnur Narin Aral, Assoc. Prof. role: SUB_INVESTIGATOR lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06344975 id: Starna Therapeutics briefTitle: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults acronym: STR-V003 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-05 date: 2024-04-03 date: 2024-04-03 name: Starna Therapeutics class: INDUSTRY briefSummary: This is a randomized, double-blind, placebo-controlled, single ascending dose escalation and two-dose study in healthy adults. This study will be conducted in healthy men and women ≥18 years old to assess the safety, tolerability and immunogenicity of STR-V003. This trial consists of two parts: Part A and Part B. conditions: Respiratory Syncytial Virus Infections studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: STR-V003/Placebo measure: Immediate unsolicited AEs for 30 minutes post-vaccination measure: Solicited injection site (local) and systemic reactions for 7 days postvaccination. measure: Unsolicited AEs for 28 days postvaccination measure: Medically attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) for the entire study duration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06344962 id: QYFYKYLL930611921 briefTitle: Clinical Effects of Absorbable and Non-absorbable Suture in Bronchial Sleeve Resection overallStatus: RECRUITING date: 2023-02-28 date: 2024-12 date: 2025-12 date: 2024-04-03 date: 2024-04-03 name: The Affiliated Hospital of Qingdao University class: OTHER briefSummary: Bronchial sleeve resection is performed as an alternative to pneumonectomy for lung cancer patients with centrally located lesions and limited cardiopulmonary reserve. Intraoperative bronchial anastomosis is very complex and difficult, mainly due to the difficulty of suturing and knotting in limited space. There are currently few studies comparing the clinical effects of absorbable and non-absorbable suture in bronchial sleeve resection. So the investigator wants to conduct a prospective study, trying to figure out this problem. conditions: Suture, Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Absorbable Suture name: Non-absorbable Suture measure: Incidence rate of anastomotic complications measure: Time of bronchial anastomosis measure: Number of stitches measure: 5-year survival rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Affiliated Hospital of Qingdao University status: RECRUITING city: Qingdao state: Shandong zip: 266000 country: China name: Zhe Wu, PhD role: CONTACT phone: +86 17863934867 email: 17863934867@163.com lat: 36.06488 lon: 120.38042 hasResults: False
nctId: NCT06344949 id: B2024-074 briefTitle: Ciprofol Versus Propofol for Tracheal Intubation in ICU overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2026-04-30 date: 2026-12-31 date: 2024-04-03 date: 2024-04-03 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: The physiological reserves of critically ill patients are relatively low, and the risk of complications related to tracheal intubation in the ICU is higher than in the operating room. ICU tracheal intubation complications account for approximately 40% -45% of patients, including severe hypotension (10% -43%), severe hypoxemia (9% -25%), and cardiac arrest (2% -3%).Ciprofol is a novel 2,6-disubstituted phenol derivative that targeting γ-aminobutyric acid type A (GABAA)-receptor. There are four indications of ciprofol that have been approved by NMPA in recent two years: sedation and anesthesia in non-tracheal intubation procedure/operation, induction and maintenance of general anesthesia, sedation during intensive care, sedation and maintenance in gynecological outpatient surgery. The aim of this study is to compare the effects of propofol and propofol on the circulatory system during tracheal intubation in ICU patients, in order to provide a safer induction sedation regimen for emergency tracheal intubation in critically ill patients. conditions: Emergency Tracheal Intubation in Critically Ill Patients studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Ciprofol name: Propofol measure: cardiovascular collapse within 30minutes from the start of the intubation procedure measure: Success rate of sedation measure: Successful intubation on the first attempt measure: Time from initiation of study drug administration to successful tracheal intubation (within 30 minutes) measure: The incidence of cardiac arrest within 30 minutes after tracheal intubation measure: The incidence of bradycardia within 30 minutes after tracheal intubation measure: The incidence of hypoxemia within 30 minutes after tracheal intubation measure: new requirement or increase of vasopressors measure: new requirement or increase of antiarrhythmic drugs sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06344936 id: HRS-1780-103 briefTitle: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07 date: 2024-07 date: 2024-04-03 date: 2024-04-03 name: Shandong Suncadia Medicine Co., Ltd. class: INDUSTRY briefSummary: The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects conditions: Chronic Kidney Disease(CKD) studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules measure: Assess the Cmax of HRS-1780 in plasma. measure: Assess the Tmax of HRS-1780 in plasma. measure: Assess the t1/2 of HRS-1780 in plasma. measure: Assess the AUC0-t of HRS-1780 in plasma. measure: Assess the AUC0-inf of HRS-1780 in plasma. measure: Assess the incidence and severity of adverse events in healthy subjects after administration of HRS-1780 tablets. sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Beijing Hospital city: Beijing state: Beijing zip: 100730 country: China name: Xin Wang role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06344923 id: KYLL briefTitle: Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-31 date: 2025-09-01 date: 2024-04-03 date: 2024-04-03 name: Qilu Hospital of Shandong University class: OTHER briefSummary: In the era of laparoscopy, ileostomy via specimen extraction site has been proposed as a novel approach for temporary ostomy creation to prevent anastomotic leak after laparoscopic low anterior rectal resection. Whether suturing the layer of the peritoneum and anterior rectus sheath affects the safety of this novel approach has not been investigated. conditions: Ileostomy - Stoma conditions: Rectal Neoplasms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing name: Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing measure: postoperative complications related to ileostomy sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06344910 id: 20230416-C1_v2 briefTitle: PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMC acronym: PROMPT-HF-AUMC overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-12 date: 2024-04-03 date: 2024-04-03 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER name: AstraZeneca name: Yale University briefSummary: This is a prospective cohort study, where we aim to investigate the effect of implementation of an electronic nudge alerting clinicians to the prescription of the 4 key pharmacological classes for the treatment of patients with heart failure and reduced ejection fraction (HFrEF) at the outpatient clinic in the Netherlands. conditions: Heart Failure With Reduced Ejection Fraction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 900 type: ESTIMATED name: Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies measure: Use of guideline-directed medical therapy (GDMT) measure: All-cause mortality measure: Hospitalisation for Heart Failure measure: other major cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) measure: renal events (>30% serum creatinine increase, hospitalization for acute kidney injury, development of end-stage kidney disease) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06344897 id: mac1 briefTitle: The Effect of Kinesio Taping in Pediatric Surgery overallStatus: COMPLETED date: 2024-02-25 date: 2024-03-21 date: 2024-04-01 date: 2024-04-03 date: 2024-04-03 name: KTO Karatay University class: OTHER name: Nigde Omer Halisdemir University name: University of Health Sciences Konya Health Application and Research Center briefSummary: This study was planned to determine the effect of kinesio taping (KT) applied to the abdominal area after surgery on pain and gas output in children aged 6-12 years who had open appendicitis surgery. conditions: Appendicitis conditions: Surgery conditions: Pain, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The effect of kinesio taping on pain in children aged 6-12 years who had open appendicitis surgery. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: The research is in a parallel group, single-blind randomized controlled experimental design.
In order to determine which group the 68 children who meet the sample selection criteria in the study group will be included in, numbers from 1 to 68 will be randomly distributed to 2 groups through a computer program (https://www.randomizer.org/) without number repetition. 34 patients will be assigned to the experimental group and 34 patients to the control group. Since the person who will actively apply the taping in the study is the researcher, only the children will be blinded, therefore a single blind design will be applied. whoMasked: PARTICIPANT count: 68 type: ACTUAL name: Kinesio taping measure: Kinesio tape applying affects pain in children aged 6-12 years who have appendicitis surgery. measure: Kinesio tape applying affects fear in children aged 6-12 years who have appendicitis surgery. measure: Kinesio taping affects gas output time in children aged 6-12 years who have appendicitis surgery sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: University of Health Sciences Konya Health Application and Research Center city: Konya state: Karatay zip: 42020 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06344884 id: 23-2619 briefTitle: Early Patient Removal of Urinary Catheters After Urogynecologic Surgery acronym: CARES2 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-07 date: 2025-07 date: 2024-04-03 date: 2024-04-03 name: University of North Carolina, Chapel Hill class: OTHER briefSummary: Management of postoperative urinary retention often requires the use of indwelling catheters. In a previous study, the investigators determined that patient removal of catheters at home is non-inferior to standard office removal on postoperative day three or four (POD3-4). The purpose of this study is to determine whether patient removal of catheters at home on postoperative day one (POD1) is noninferior to removal on POD 3-4. conditions: Urinary Retention Postoperative conditions: Postoperative Urinary Tract Infection conditions: Catheter Site Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 128 type: ESTIMATED name: Early catheter removal measure: Number of patients with ongoing urinary retention (noninferiority) measure: Number of patient contacts for voiding dysfunction by Type measure: Total patient contacts for voiding dysfunction Combined measure: Number of patients treated for postoperative UTI. measure: Number of patients with ongoing urinary retention measure: Patient Satisfaction Survey Score-Pain measure: Patient Satisfaction Survey Score-Ease of Use measure: Patient Satisfaction Survey Score-Satisfaction measure: Patient Satisfaction Survey Score-Likelihood to Use Again sex: FEMALE minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UNC Health Rex city: Raleigh state: North Carolina zip: 27607 country: United States name: Lauren Tholemeier, MD role: CONTACT phone: 984-974-0496 email: lauren_tholemeier@med.unc.edu lat: 35.7721 lon: -78.63861 hasResults: False
nctId: NCT06344871 id: 002 briefTitle: Exploratory Study Using a New Head-only PET Scanner / ExploreNeuroLF overallStatus: RECRUITING date: 2024-03-13 date: 2024-11-30 date: 2024-11-30 date: 2024-04-03 date: 2024-04-05 name: Positrigo AG class: INDUSTRY name: University of Zurich name: University of Leipzig briefSummary: The "NeuroLF prototype" is a small aperture PET scanner. The NeuroLF prototype will be used with patients, which have just finished their regularly scheduled PET examination on a clinical whole body PET system. The radioactive tracer used for this procedure will still be active. This remaining acitivity will be used for an image acquisition with the NeuroLF prototype without the need for an additional radioactive tracer dose.
The control intervention is be a brain PET scan as part of standard clinical routine. It will be done immediately before the scan on the NeuroLF prototype. conditions: Brain Diseases studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 70 type: ESTIMATED name: NeuroLF name: Conventional PET scan measure: PET Image of the Brain measure: Ease of Placement (Usability) measure: Usage of accessories for patient placement (Usability) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Leipzig status: RECRUITING city: Leipzig country: Germany name: Henryk Barthel, Prof.Dr. role: CONTACT phone: +49 341 97 18082 email: Henryk.Barthel@medizin.uni-leipzig.de name: Henryk Barthel, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 51.33962 lon: 12.37129 facility: University Hospital Zurich status: NOT_YET_RECRUITING city: Zürich country: Switzerland name: Martin Hüllner, Prof. Dr. role: CONTACT phone: +41 44 255 25 80 email: martin.huellner@usz.ch name: Martin Hüllner, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 47.36667 lon: 8.54999 hasResults: False